Cadrenal Therapeutics, Inc. Logo

Cadrenal Therapeutics, Inc.

Developing novel anticoagulant therapies for high-risk cardiovascular patients.

CVKD | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
822 A1A NORTH, 32082 PONTE VEDRA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing novel anticoagulant therapies to address critical gaps in cardiovascular care. The company's mission is to create safer and more effective treatments with greater predictability and control, thereby reducing the risks of both clotting and bleeding. Its clinical-stage pipeline includes two primary assets: tecarfarin, an oral vitamin K antagonist for chronic use, and frunexian, a parenteral Factor XIa inhibitor for acute hospital settings. Cadrenal targets underserved, high-risk patient populations, including those with end-stage kidney disease and atrial fibrillation, as well as patients with implanted cardiac devices, aiming to reshape the standards of care in anticoagulation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cadrenal Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cadrenal Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cadrenal Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America APRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.